Blood-based PAaM score for predicting HCC risk in patients withHBV-related advanced fibrosis receiving nucleos(t)ide analogtherapy
Liver Cancer · 09.11.2026
DOI: 10.1159/lic/admag029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 09.11.2026. Verfasst von Mizuki Kawachi und 18 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
A composite score of clinical and molecular biomarkers, PAaM score, was associated with the risk of hepatocellular carcinoma (HCC) in advanced fibrosis in two independent large-scale phase 3 biomarker studies in the US; however, Asian patients and those with hepatitis B virus (HBV) infection receiving nucleos(t)ide analog (NUC) therapy were markedly underrepresented.
Methods
This study retrospectively analyzed 291 patients with HBV-related advanced fibrosis prospectively enrolled at three tertiary-care centers in Japan. All patients had received NUCs for at least six months. The PAaM score was calculated by integrating the PLSec molecular biomarker panel, serum AFP, and the aMAP score. Patients were stratified into high-, intermediate-, and low-risk groups using pre-defined cut-offs. The primary analysis was the association of PAaM risk groups with incident HCC, accounting for competing mortality. In secondary analyses, performance was compared with aMAP, PAGE-B, and modified PAGE-B, mainly using the time-dependent area under the precision-recall curve (AUPRC).
Results
During a median follow-up of 8.3 years, 35 patients developed HCC. PAaM classified 8%, 29%, and 63% of patients into high-, intermediate-, and low-risk groups, respectively. The HCC incidence rates were 4.26, 2.71, and 0.82 per 100 person-years for high-, intermediate-, and low-risk patients, respectively (P = 0.003). The PAaM score was significantly associated with incident HCC, with a sub-distribution hazard ratio of 4.68 (95% CI 1.87 – 11.7) for high-risk versus low-risk patients. PAaM achieved the numerically highest AUPRC (0.21 at 3 years, 3.8-fold above the event prevalence).
Conclusion
The PAaM score was externally validated as a risk stratification biomarker in Japanese patients with HBV-related advanced fibrosis receiving NUC therapy.
Zitieren
APA
Kawachi, M., Fujiwara, N., Honda, T., Tsukimoto, M., Tameda, M., Tanaka, H., Selvakumar, P., Raman, I., Katz, C., Suzuki, H., Kanzaki, H., Suzuki, T., Ito, T., Kawashima, H., BAUMERT, T., Singal, A., Toyoda, H., Hoshida, Y., & Nakagawa, H. (2026). Blood-based PAaM score for predicting HCC risk in patients withHBV-related advanced fibrosis receiving nucleos(t)ide analogtherapy. Liver Cancer. https://doi.org/10.1159/lic/admag029
Vancouver
Kawachi M, Fujiwara N, Honda T, Tsukimoto M, Tameda M, Tanaka H, et al. Blood-based PAaM score for predicting HCC risk in patients withHBV-related advanced fibrosis receiving nucleos(t)ide analogtherapy. Liver Cancer. 2026. doi:10.1159/lic/admag029
BibTeX
@article{Kawachi2026,
author = {Kawachi, Mizuki and Fujiwara, Naoto and Honda, Takashi and Tsukimoto, Mone and Tameda, Masahiko and Tanaka, Hideaki and Selvakumar, Pratibha and Raman, Indu and Katz, Courtney and Suzuki, Hiroyuki and Kanzaki, Hiroaki and Suzuki, Takaya and Ito, Takanori and Kawashima, Hiroki and BAUMERT, Thomas and Singal, Amit and Toyoda, Hidenori and Hoshida, Yujin and Nakagawa, Hayato},
title = {Blood-based PAaM score for predicting HCC risk in patients withHBV-related advanced fibrosis receiving nucleos(t)ide analogtherapy},
journal = {Liver Cancer},
year = {2026},
doi = {10.1159/lic/admag029}
}
EUVIMED